Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company addressing high unmet medical needs in the areas of immuno-oncology, immunology, as well as viral, neurodegenerative and cardiometabolic diseases. Secarna's mission is to maximize the performance and output of its proprietary LNAplusTM antisense oligonucleotide discovery platform, as well as to develop highly specific, safe, and efficacious best-in-class antisense therapies for challenging or currently undruggable targets. With over 15 development programs, including proprietary pipeline projects as well as partnered programs, we focus on targets in indications where antisense-based approaches have clear benefits over other therapeutic modalities, Secarna is the leading independent European antisense drug discovery and development company.
